Glycomimetics (GLYC) PT Lowered to $18 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
GlycoMimetics Reports Top-line Results From Pfizer’s Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease
August 2, 2019 8:43 PM EDTROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) reported that Pfizer Inc. (NYSE: PFE) announced today that the Phase 3 Rivipansel (GMI-1070): Evaluating Safety, Efficacy and Time to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints. The objective of the trial was to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell... More
GlycoMimetics Reports Second Quarter 2019 Financial Results and Recent Operational Highlights
August 1, 2019 7:30 AM EDTAnnounced completion of enrollment in Pfizers Phase 3 clinical trial evaluating rivipansel, the Companys lead investigational drug candidate, in sickle cell disease (SCD) Enrolled first patient in... More
